The Contrast Of Biological Behaviour Between Triple-negative Breast Cancer And Non-triple-negetive Breast Cancer

Objective Breast cancer is one of the most frequent malignant tumor in female, at the same time it also is a kind of heterogeneity of higher malignant tumors. While the new type of breast cancer(TNBC), triple-negative breast cancer, is named in the recent years whose immunohistochemistry is not express estrogen receptor(ER), progesterone receptor(PR) and human epidermal growth factor eceptor-2(Her-2/C-erbB-2). And this kind of breast cancer have more invasion and worse prognosis. Respecting its feature of not express these three receptors, TNBC can not use the orthodox Endocrine therapy and Herceptin. At present its systemic treatments are limited. Therefore to investigate the contrast of clinical pathology characteristic and prognosis between triple-negative breast cancer and non-triple-negetive breast cancer could have certain practical significance and the present study hotspot. Our study aims at summarize the features which are different between this two groups of breast cancer, in order to guide clinical indiidual therapy, prognosis and further genetic study lay solid foundation, etc.Methods To collect 231 breast cancer patients between Jan, 2002 to Dec, 2004 in the affiliated hospital of Ningxia medicial university and the people hospital of Yinchuan, which were final diagnosis by pathohistology, and have complete follow-up data of five years. All of the patients are women. In the samples, 40 patients are detected non–express estrogen receptor(ER), progesterone receptor(PR) and human epidermal growth factor eceptor-2(C-erbB-2) by immunohistochemistry. To separate the 231 patients into two group by immunohistochemistry result, triple-negetive group and non-triple-negetive group. To contrast the biological behaviour between the two group, include clinical pathology characteristics and 5 year survival and so on. The results use statistical analysis software SPSS11.5.Results 1. The triple-negetive group is accounted to 17.3%. The contrast of age, catamenia, nation and onco- family history between the two group have no statistical significance. 2. For clinical pathology characteristics, the triple-negetive group got larger tumor size than the non-triple-negetive group, and the result has statistical significance (P<0.05). But the contrast of primarily site, lymph nodes number, clinical stage, patho- category and patho-class have no statistical significance. 3. Compare to the the non-triple-negetive group, in the same treatment premise, the triple-negetive group transfer rate of relapse and metastasis(P<0.05), especially the internal transfer rate is higher(P<0.05). 4. The triple-negetive group's 3 years and 5 years of survival rate lower then the non-triple-negetive group obviously(P<0.05). Further discovery that on equal clinical stage and both in lymph nodes positive patients, the triple-negetive group is worse than the non-triple-negetive group on the 5 years survival status (P<0.05). 5. Use cox ratio analysis model to do prognosis analysis, Patient age group, the primary tumor size, and the clinical stages and whether for " triple-negetive " are independent risk factors for breast cancer.Conclusions 1. To contrast triple-negetive with non-triple-negetive breast cancer, triple-negetive breast cancer has strong local recurrence and metastasis of invasive and internal transfer rate is high. 2. To contrast triple-negetive with non-triple-negetive breast cancer, triple-negetive breast cancer has poor prognosis, and 5 years of survival rate is low. It may relate with the treatment is limited and the first chemotherapy CAF/CMF drug resistance. 3. The non-express of ER,PR,HER-2 is independent influent factor of prognosis.